5 Key Takeaways

• 1

  Most adverse effects listed in statin labels lack support from randomized controlled trials, according to a meta-analysis of 154,664 participants.

• 2

  Only 4 out of 66 prespecified adverse outcomes showed significant excess risk, with small absolute annual risks for liver abnormalities and edema.

• 3

  No significant excess risk was found for 62 outcomes, including cognitive impairment and depression, which are mentioned in statin product labels.

• 4

  The analysis indicated a dose-dependent relationship for liver enzyme elevations, particularly with atorvastatin 80 mg daily.

• 5

  The findings suggest a need for revision of statin labels to provide accurate information for clinicians and patients regarding risks.